Showing results (1101-1110 of 1,120) with videos related to
Sort By:
Pageof 112
Cancer Research Communications|December 5, 2024
Autofluorescence Virtual Staining System for H&E Histology and Multiplex Immunofluorescence Applied to Immuno-Oncology Biomarkers in Lung CancerJessica Loo, Marc Robbins, Carson McNeil, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent developmentJoyce A O'Shaughnessy, Gary J Kelloff, Gary B Gordon, et al.Journal of Cellular Biochemistry. Supplement|January 1, 1996
Strategy and planning for chemopreventive drug development: clinical development plans IIG J Kelloff, J A Crowell, E T Hawk, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2015
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400Roy S Herbst, David R Gandara, Fred R Hirsch, et al.Critical Care Medicine|March 15, 2024
A Modified Delphi Consensus Approach to Define Entrustable Professional Activities for Neurocritical Care Advanced Practice ProvidersDaniel S Harrison, Erika J Sigman, Judy H Ch'ang, et al.Cancer Research|January 10, 2023
Challenges to Using Big Data in CancerShawn M Sweeney, Hisham K Hamadeh, Natalie Abrams, et al.Cancer Research|January 10, 2023
Case Studies for Overcoming Challenges in Using Big Data in CancerShawn M Sweeney, Hisham K Hamadeh, Natalie Abrams, et al.Molecular and Cellular Biochemistry|July 8, 2011
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical researchSilvio E Perea, Idania Baladron, Yanelda Garcia, et al.Molecular and Cellular Biochemistry|June 26, 2008
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivoSilvio E Perea, Osvaldo Reyes, Idania Baladron, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future ApplicationsKenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.Pageof 112